Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Moderna's Market Reaction: Understanding the Sell-the-News Phenomenon After Positive Trial Results

Despite positive trial results, Moderna's stock dropped 7.32%, highlighting the sell-the-news trend in biotech.

Aug 25, 2026
Pharmaceutical

McKesson's $2.25 Billion Precision Medicine Acquisition: What It Means for Investors

McKesson's $2.25 billion acquisition of Precision Medicine Group signals a strategic move in oncology and life sciences.

Aug 25, 2026
Pharmaceutical

Merck and Moderna's mRNA Cancer Vaccine Shows Promise in Phase 3 Trials

Merck and Moderna's mRNA-based cancer vaccine for melanoma shows strong Phase 3 trial results, signaling a shift in cancer therapy.

Aug 24, 2026
Pharmaceutical

Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics

Eli Lilly's recent FDA approval for an Alzheimer's blood test signals a pivotal moment in diagnostics, impacting investors and patients alik…

Aug 24, 2026
Pharmaceutical

Merck and Moderna's Phase 3 Success: A Milestone in Cancer Vaccination

Merck and Moderna report significant success in their Phase 3 trial, reinforcing the role of KEYTRUDA in oncology.

Aug 24, 2026
Pharmaceutical

Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics

Eli Lilly's FDA approval for an Alzheimer's blood test could reshape the diagnostics landscape and boost investor sentiment.

Aug 24, 2026
Pharmaceutical

TG Therapeutics on the Rise: Exploring the Potential of Takeover Speculation

TG Therapeutics gains traction amid takeover rumors, reflecting broader M&A interest in the pharmaceutical sector.

Aug 23, 2026
Pharmaceutical

Moderna's Cancer Vaccine Breakthrough: Implications for Investors and Biotech Traders

The recent Phase 3 trial results for Moderna's cancer vaccine have sent shockwaves through the biotech sector, raising investor sentiment dr…

Aug 23, 2026
Pharmaceutical

Capricor Therapeutics Faces PDUFA Date: What Investors Should Know

Capricor's stock dropped nearly 8% as it awaits an FDA decision on Deramiocel for Duchenne muscular dystrophy.

Aug 22, 2026
Pharmaceutical

Moderna's Cancer Vaccine Triumph: What This Means for Investors

Moderna's stock surged 176.97% after successful Phase 3 trial results for its cancer vaccine, signaling potential market shifts.

Aug 22, 2026
Pharmaceutical

Werewolf Therapeutics (HOWL) and Ambros Therapeutics Join Forces in Strategic Merger

Werewolf Therapeutics and Ambros Therapeutics announce an all-stock merger and a $150 million private placement, focusing on oncology.

Aug 21, 2026
Pharmaceutical

TG Therapeutics (TGTX) Sees Stock Surge Amid Acquisition Buzz

TG Therapeutics is gaining traction as speculation about a potential acquisition heats up, fueled by its drug BRIUMVI's FDA approval.

Aug 21, 2026